Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.54 |
| ▸ | CDK4 | P11802 | 6/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024205 | 0.92 | CDK2 (0.56) | CDK2CDK4CDK1KCNH2 | |
| SCHEMBL4030405 | 0.89 | CDK2 (0.63) | CDK2CDK4CDK1KCNH2 | |
| SCHEMBL4021126 | 0.86 | CDK2 (0.53) | CDK2CDK4CDK1KCNH2 | |
| SCHEMBL6600221 | 0.79 | CDK2 (0.46) | CDK2CDK4 | |
| SCHEMBL5098705 | 0.78 | CDK2 (0.53) | CDK2CDK4CDK1 | |
| SCHEMBL4026053 | 0.76 | CDK2 (0.70) | CDK2CDK4CDK1 | |
| SCHEMBL6600811 | 0.75 | CDK2 (0.50) | CDK2CDK4 | |
| SCHEMBL6604661 | 0.74 | CDK2 (0.47) | CDK2CDK4 | |
| SCHEMBL4023449 | 0.72 | CDK2 (0.80) | CDK2CDK4CDK1 | |
| SCHEMBL5098833 | 0.72 | CDK2 (0.74) | CDK2CDK4CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485375-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-06-17 | — | — | EP | disclosed |
| US-7485638-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-20050256311-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1485375-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076435-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256311-A1 | Pyrimidine compounds | TYMP, TYMS, CCNT1 | CDK2 24/4885CDK4 48/4885CDK1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.